by Plus Therapeutics | Sep 17, 2025 | GBM, PBC
Each September, Childhood Cancer Awareness Month (#CCAM) serves as a powerful reminder to honor children and families affected by pediatric cancer and to raise awareness for the urgent need for new treatment options. At Plus Therapeutics (Nasdaq: PSTV), we are deeply...
by Plus Therapeutics | Sep 15, 2025 | Uncategorized
Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics (Nasdaq: PSTV), recently joined Daniel Levine, host of The Bio Report podcast by Levine Media Group, to discuss the challenges of treating brain tumors, the limitations of current...
by Plus Therapeutics | Sep 8, 2025 | Uncategorized
Marc Hedrick, M.D., President and CEO of Plus Therapeutics (NASDAQ: PSTV), was recently featured in Pharma’s Almanac, where he shared insights on how precision medicine is reshaping the future of oncology. Precision Medicine in Cancer Care In the article, Dr. Hedrick...
by Plus Therapeutics | Sep 4, 2025 | LM
Last month, several of the world’s leading experts in leptomeningeal metastases (LM) came together at the American Society of Clinical Oncology (ASCO) / Society for Neuro-Oncology (SNO) CNS Metastases Conference to share insights, research, and clinical updates on...
by Plus Therapeutics | Aug 20, 2025 | LM
Last week, the leadership teams of Plus Therapeutics and CNSide Diagnostics came together onsite at the SNO/ASCO 2025 CNS Metastases Conference to advance the dialogue on leptomeningeal metastases (LM). LM Symposium The jointly sponsored LM presentation and panel...
Recent Comments